ArticleCancer research2018
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).International journal of molecular medicine · 2025Review
- Telomere-metabolism-immunity axis in sarcoma: Immune evasion mechanisms and therapeutic strategies.Clinical and translational medicine · 2025Review
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.Current treatment options in oncology · 2025Review
- Measles Virus-Based Genetic Modifications: Progress in Hematological Malignancy Treatment.OncoTargets and therapy · 2025Review
- Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.Frontiers in immunology · 2025Review
- Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells.Acta pharmacologica Sinica · 2024Article
- VSVNature communications · 2024Article
- Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer.Nature communications · 2024Article
- GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer.Frontiers in immunology · 2024Article
- Recent progress in combination therapy of oncolytic vaccinia virus.Frontiers in immunology · 2024Review
- Immunobiology of cancer stem cells and their immunoevasion mechanisms.Molecular biology reports · 2023Review
- Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.Cancer biology & medicine · 2023Review
- Oncolytic vaccinia virus and cancer immunotherapy.Frontiers in immunology · 2023Review
- Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.Molecular cancer · 2022Review
- Review
- Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.Molecular therapy oncolytics · 2022Article
- Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.Journal for immunotherapy of cancer · 2022Review
- Generation of Human Lung Organoid Cultures from Healthy and Tumor Tissue to Study Infectious Diseases.Journal of virology · 2022Article
- Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
Oncolytic viruses pose many questions in their use in cancer therapy. In this study, we assessed the potential of mpJX-594 (mouse-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection, to target the tumor vasculature, produce immune activation and tumor cell killing more widespread than the infection, and suppress invasion and metastasis. These actions were examined in RIP-Tag2 transgenic mice with pancreatic neuroendocrine tumors that developed spontaneously and progressed as in humans. mpJX-594 initially infected tumor vascular endothelial cells, leading to vascular pruning and prolonged leakage in tumors but not in normal organs; parallel effects were observed in U87 gliomas. Viral infection spread to tumor cells, where tumor cell killing was much more widespread than the infection. Widespread tumor cell killing at 5 days was prevented by depletion of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.